CHRONIC TREATMENT WITH ANTI-ENDOTHELIN ANTIBODIES FAILS TO MODIFY THEDEVELOPMENT OF HYPERTENSION IN STROKE-PRONE SPONTANEOUSLY HYPERTENSIVE RATS AND DOCA-SALT HYPERTENSIVE RATS

This study was designed to assess whether blocking endogenous endothel in with anti-endothelin antibodies could alter the development of hype rtension in stroke-prone spontaneously hypertensive rats (SHR) and DOC A-salt treated rats. Specific anti-endothelin antibodies were produced in rabbits by standard methods. The amount of anti-endothelin antibod ies employed in this study blocked the hypertensive effect of endothel in-1, 750 ng/kg, by 55% in conscious rats. Intravenous injection of an ti-endothelin antibodies as a bolus twice a week for 3 weeks did not a ffect the rise in blood pressure of stroke-prone SHR (268 +/- 8 mmHg, n = 8) compared to control stroke-prone SHR (256 +/- 7 mmHg, n = 8) tr eated with normal rabbit serum. Intravenous administration of anti-end othelin antibodies in a same manner also failed to alter the developme nt of hypertension in DOCA-salt treated rats (160 +/- 6 mmHg in anti-e ndothelin antibodies-treated group, n = 7 compared to 164 +/- 5 mmHg i n normal rabbit serum-treated group, n = 7). The administration of ant i-endothelin antibodies did not induce any significant changes in body weight, urine volume and urinary sodium excretion in stroke-prone SHR and DOCA-salt treated rats compared to those treated with normal rabb it serum. These findings suggest that circulating endothelin might not play a major role in the regulation of blood pressure in stroke-prone SHR and DOCA-salt treated rats.